Impact Therapeutics, Inc.

This study tested a new oral medication called IMP4297 for women with advanced ovarian cancer that has a specific genetic change (BRCA mutation) and has stopped responding to at least two standard treatments. The main goal was to see if the drug could shrink tumors and control th…

This early-stage study aimed to understand how the body processes a single dose of an experimental cancer drug called IMP4297. Six healthy adult male volunteers took the drug so researchers could track how it was absorbed, broken down, and eliminated. The goal was to gather basic…

This study aimed to see if two different capsule strengths (10 mg and 20 mg) of an experimental cancer drug called IMP4297 are absorbed by the body in the same way. It involved 28 healthy Chinese male volunteers who each took the drug in two different forms. The main goal was to …

This study aimed to see if two different capsule strengths of a potential cancer drug, IMP4297, are absorbed by the body in the same way. It involved 36 healthy Chinese male volunteers who took the drug after a meal. The main goal was to gather data on how the drug moves through …